1,000,000 Shares1 SHARPSPRING, INC. Common Stock UNDERWRITING AGREEMENT
Exhibit 1.1
Execution Version
1,000,000 Shares1
Common Stock
December 16,
2020
Xxxxxxx & Company, LLC
Lake Street Capital Markets, LLC
As
Representatives of the several Underwriters
c/o
Needham & Company, LLC
000
Xxxx Xxxxxx, 00xx Xxxxx
Xxx
Xxxx, Xxx Xxxx 00000
x/x
Xxxx Xxxxxx Xxxxxxx Xxxxxxx, LLC
000
Xxxxxx Xxxxxx Xxxxx, Xxxxx 000
Xxxxxxxxxxx,
Xxxxxxxxx 00000
Ladies
and Gentlemen:
SharpSpring, Inc.,
a Delaware corporation (the “Company”), proposes to
issue and sell 1,000,000 shares (the “Firm
Shares”) of the Company’s common stock, par value $.001
per share (the “Common Stock”), to you and to the
several other Underwriters named in Schedule I hereto
(collectively, the “Underwriters”), for whom you are
acting as representatives (the “Representatives”). The
stockholder of the Company named in Schedule II hereto (the
“Selling Stockholder”) has agreed to grant to you and
the other Underwriters an option (the “Option”) to
purchase up to an additional 150,000 shares of Common Stock, on the
terms and for the purposes set forth in Section 1(b) (the
“Option Shares”). The Firm Shares and the Option Shares
are referred to collectively herein as the
“Shares.”
The
Company and the Selling Stockholder confirm as follows their
respective agreements with the Representatives and the several
other Underwriters.
1. Agreement
to Sell and Purchase.
(a) On the basis of the
representations, warranties and agreements of the Company herein
contained and subject to all the terms and conditions of this
Agreement, (i) the Company agrees to issue and sell the Firm
Shares to the several Underwriters and (ii) each of the
Underwriters, severally and not jointly, agrees to purchase from
the Company the respective number of Firm Shares set forth opposite
that Underwriter’s name in Schedule I hereto, at the
purchase price of $14.10 for each Firm Share.
________________
1*
Plus an option to
purchase up to an additional 150,000 shares.
1
(b) Subject to all the
terms and conditions of this Agreement, the Selling Stockholder
grants the Option to the several Underwriters to purchase,
severally and not jointly, up to 150,000 Option Shares at the
same price per share as the Underwriters shall pay for the Firm
Shares. The Option may be exercised at any time in whole, or from
time to time in part, on or before the 30th day after the date of
this Agreement upon written or telegraphic notice (an “Option
Shares Notice”) by the Representatives to the Company and the
Selling Stockholder no later than 12:00 noon, New York City
time, at least two and no more than five business days before the
date specified for closing in the Option Shares Notice (an
“Option Closing Date”), setting forth the aggregate
number of Option Shares to be purchased and the time and date for
such purchase. On an Option Closing Date, the Selling Stockholder
will sell to the Underwriters the number of Option Shares set forth
in the applicable Option Shares Notice, and each Underwriter will
purchase such percentage of the Option Shares as is equal to the
percentage of Firm Shares that such Underwriter is purchasing, as
adjusted by the Representatives in such manner as it deems
advisable to avoid fractional shares.
2. Delivery
and Payment. Delivery of the
Firm Shares shall be made to or as instructed by the
Representatives for the accounts of the several Underwriters in a
form reasonably acceptable to the Representatives against payment
by the Underwriters of the purchase price by wire transfer payable
in same-day funds to the order of the Company at the office of
Xxxxxxx & Company, LLC, 000 Xxxx Xxxxxx, 00xx Xxxxx, Xxx
Xxxx, Xxx Xxxx 00000, at 10:00 a.m., New York City time, on
the second (or, if the purchase price set forth in
Section 1(a) hereof is determined after 4:30 p.m., New York
City time, the third) business day after the date of this
Agreement, or at such time on such other date, not later than seven
business days after the date of this Agreement, as may be agreed
upon by the Company and the Representatives (such date is
hereinafter referred to as the “Closing
Date”).
To the
extent the Option is exercised, delivery of the Option Shares
against payment by the Underwriters by wire transfer payable in
same-day funds to the order of the Selling Stockholder will take
place at the offices specified above for the Closing Date at the
time and date (which may be the Closing Date) specified in the
applicable Option Shares Notice.
The
Shares shall be in definitive form and shall be registered in such
names and in such denominations as the Representatives shall
request at least two business days prior to the Closing Date or the
applicable Option Closing Date, as the case may be, by written
notice to the Company, and shall be delivered by or on behalf of
the Company as instructed by the Representatives through the
facilities of The Depository Trust Company (“DTC”). The
Company agrees to make certificates, if any, representing the
Shares or evidence of their issuance available for inspection at
least 24 hours prior to the Closing Date or the applicable
Option Closing Date, as the case may be. If the Representatives so
elect, delivery of the Shares may be made by credit through full
FAST transfer to the accounts at DTC designated by the
Representatives.
The
cost of original issue tax stamps and other transfer taxes, if any,
in connection with the issuance and delivery of the Firm Shares and
Option Shares by the Company to the respective Underwriters shall
be borne by the Company. The Company will pay and save each
Underwriter and any subsequent holder of the Shares harmless from
any and all liabilities with respect to or resulting from any
failure or delay in paying federal and state stamp and other
transfer taxes, if any, which may be payable or determined to be
payable in connection with the original issuance or sale to such
Underwriter of the Shares.
3. Representations
and Warranties of the Company. The Company
represents, warrants and covenants to each Underwriter
that:
2
(a) The Company meets
the requirements for the use of Form S-3. A registration statement
(Registration No. 333-222850) on Form S-3 relating to the
Shares, including a base prospectus relating to the Shares (the
“Base Prospectus”) and such amendments thereto as may
have been required to the date of this Agreement, has been prepared
by the Company under the provisions of the Securities Act of 1933,
as amended (the “Act”), and the rules and regulations
(collectively referred to as the “Rules and
Regulations”) of the Securities and Exchange Commission (the
“Commission”) thereunder, has been filed with the
Commission, and has been declared effective by the Commission, and
the offering of the Shares complies with Rule 415 under the Act. A
final prospectus supplement to the Base Prospectus relating to the
Shares and the offering thereof will be filed promptly by the
Company with the Commission in accordance with Rule 424(b) of the
Rules and Regulations (“Rule 424(b)”) (such final
prospectus supplement, as so filed, the “Prospectus
Supplement”). Such registration statement at any given time,
including the amendments thereto to such time, the exhibits and any
schedules thereto at such time, the documents otherwise deemed to
be a part thereof or included therein by the Rules and Regulations
(including Rule 430B thereof), and any registration statement
relating to the offering contemplated by this Agreement and filed
pursuant to Rule 462(b) of the Rules and Regulations (“Rule
462(b)”), is herein called the “Registration
Statement.” The term “preliminary prospectus”
means any preliminary prospectus (including any preliminary
prospectus supplement) relating to the Shares and the offering
thereof as first filed with the Commission pursuant to Rule 424(b).
The term “Prospectus” means the Base Prospectus
together with the Prospectus Supplement, except that if such Base
Prospectus is amended or supplemented on or prior to the date on
which the Prospectus Supplement was first filed pursuant to Rule
424(b), the term “Prospectus” shall mean the Base
Prospectus as so amended or supplemented and as supplemented by the
Prospectus Supplement. Any reference herein to the Registration
Statement, the Base Prospectus, a preliminary prospectus, the
Prospectus Supplement, or the Prospectus shall be deemed to refer
to and include the documents incorporated by reference therein, and
any reference herein to the terms “amend,”
“amendment” or “supplement” with respect to
the Registration Statement, the Base Prospectus, a preliminary
prospectus, the Prospectus Supplement, or the Prospectus shall be
deemed to refer to and include the filing of any document under the
Securities Exchange Act of 1934, as amended (the “Exchange
Act”), after the time the Registration Statement initially
became effective (the “Effective Date”), the date of
the Base Prospectus, any preliminary prospectus, the Prospectus
Supplement, or the Prospectus, as the case may be, and deemed to be
incorporated therein by reference. The term “Issuer Free
Writing Prospectus” means any “issuer free writing
prospectus,” as defined in Rule 433 of the Rules and
Regulations (“Rule 433”), relating to the Shares in the
form filed or required to be filed with the Commission or, if not
required to be filed, in the form retained in the Company’s
records pursuant to Rule 433(g).
(b) No order preventing
or suspending the use of the Base Prospectus, any preliminary
prospectus, the Prospectus Supplement, the Prospectus or any Issuer
Free Writing Prospectus has been issued by the Commission, and no
stop order suspending the effectiveness of the Registration
Statement (including any related registration statement filed
pursuant to Rule 462(b)) or any post-effective amendment thereto
has been issued, and no proceeding for that purpose has been
initiated or, to the Company’s knowledge, threatened by the
Commission. On the Effective Date, on the date the Base Prospectus,
any preliminary prospectus, the Prospectus Supplement, or the
Prospectus is first filed with the Commission pursuant to Rule
424(b) (if required), at all times during the period through and
including the Closing Date and, if later, the applicable Option
Closing Date and when any post-effective amendment to the
Registration Statement becomes effective or any amendment or
supplement to the Prospectus is filed with the Commission, the
Registration Statement and the Prospectus (as amended or as
supplemented if the Company shall have filed with the Commission
any amendment or supplement thereto), including the financial
statements included or incorporated by reference in the Prospectus,
did and will comply with all applicable provisions of the Act, the
Exchange Act, the rules and regulations of the Commission under the
Exchange Act (the “Exchange Act Rules and
Regulations”), and the Rules and Regulations and will contain
all statements required to be stated therein in accordance with the
Act, the Exchange Act, the Exchange Act Rules and Regulations, and
the Rules and Regulations. As of the applicable effective date as
to each part of the Registration Statement, no part of the
Registration Statement, the Prospectus or any such amendment or
supplement thereto did or will contain an untrue statement of a
material fact or omit to state a material fact required to be
stated therein or necessary in order to make the statements therein
not misleading. At the Effective Date, the date the Base Prospectus
or any amendment or supplement to the Base Prospectus, including
any preliminary prospectus or the Prospectus Supplement, is filed
with the Commission, the date of first use of any preliminary
prospectus or the Prospectus Supplement, and at the Closing Date
and, if later, the applicable Option Closing Date, the Prospectus
did not and will not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the
statements therein, in the light of the circumstances under which
they were made, not misleading.
3
As of
the Applicable Time, neither (x) the Issuer General Use Free
Writing Prospectus(es) (as defined below) issued at or prior to the
Applicable Time (as defined below), the Pricing Prospectus (as
defined below) and the information listed on Schedule III, all
considered together (collectively, the “General Disclosure
Package”), nor (y) any individual Issuer Limited Use Free
Writing Prospectus, when considered together with the General
Disclosure Package, included any untrue statement of a material
fact or omitted to state any material fact necessary in order to
make the statements therein, in the light of the circumstances
under which they were made, not misleading.
As used
in this subsection and elsewhere in this Agreement:
“Applicable
Time” means 7:30 a.m. (Eastern time) on December 16, 2020 or
such other time as agreed by the Company and the
Representatives.
“Issuer
General Use Free Writing Prospectus” means any Issuer Free
Writing Prospectus that is intended for general distribution to
prospective investors, as evidenced by its being specified in
Schedule III hereto.
“Issuer
Limited Use Free Writing Prospectus” means any Issuer Free
Writing Prospectus that is not an Issuer General Use Free Writing
Prospectus.
“Pricing
Prospectus” means the Base Prospectus, as amended or
supplemented immediately prior to the Applicable Time, including
any document incorporated by reference therein and any prospectus
supplement deemed to be a part thereof. For purposes of this
definition, information contained in a form of prospectus that is
deemed retroactively to be a part of the Registration Statement
pursuant to Rule 430B shall be considered to be included in the
Pricing Prospectus only if the actual time that form of prospectus
is filed with the Commission pursuant to Rule 424(b) is prior to
the Applicable Time.
Each
Issuer Free Writing Prospectus, as of its issue date and at all
subsequent times through the completion of the public offer and
sale of the Shares or until any earlier date that the issuer
notified or notifies the Representatives as described in the next
sentence, did not, does not and will not include any information
that conflicted, conflicts or will conflict with the information
contained in the Registration Statement or the Prospectus,
including information in any document incorporated by reference
therein that has not been superseded or modified. If there occurs
an event or development as a result of which the General Disclosure
Package would include an untrue statement of a material fact or
would omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances then
prevailing, not misleading, the Company will promptly notify the
Representatives so that any use of the General Disclosure Package
may cease until it is amended or supplemented to correct such
untrue statement or omission.
The
foregoing representations and warranties in this Section 3(b)
do not apply to any statements or omissions made in reliance on and
in conformity with information relating to any Underwriter
furnished in writing to the Company by the Representatives
specifically for inclusion in the Registration Statement, the
Prospectus Supplement, the Pricing Prospectus, the Prospectus or
any Issuer Free Writing Prospectus or any amendment or supplement
thereto. The Company acknowledges that the statements set forth in
the fifth and tenth through thirteenth paragraphs under the heading
“Underwriting” in the Pricing Prospectus and the
Prospectus (the “Underwriter Information”) constitute
the only information relating to any Underwriter furnished in
writing to the Company by the Representatives specifically for
inclusion in the Registration Statement, the Prospectus Supplement,
the Pricing Prospectus, the Prospectus and any Issuer Free Writing
Prospectus.
(c) (i) At the earliest
time after the filing of the Registration Statement that the
Company or another offering participant made a bona fide offer (within the meaning of
Rule 164(h)(2) of the Rules and Regulations) of the Shares and (ii)
as of the date hereof, the Company was not and is not an Ineligible
Issuer (as defined in Rule 405 of the Rules and Regulations
(“Rule 405”)), without taking account of any
determination by the Commission pursuant to Rule 405 that it is not
necessary that the Company be considered an Ineligible
Issuer.
4
(d) The documents that
are incorporated by reference in the Base Prospectus, any
preliminary prospectus, the Pricing Prospectus and the Prospectus
or from which information is so incorporated by reference, when
they became or become effective or were or are filed with the
Commission, as the case may be, complied or will comply in all
material respects with the requirements of the Act or the Exchange
Act, as applicable, and the Rules and Regulations or the Exchange
Act Rules and Regulations, as applicable; and any documents so
filed and incorporated by reference subsequent to the Effective
Date shall, when they are filed with the Commission, comply in all
material respects with the requirements of the Act or the Exchange
Act, as applicable, and the Rules and Regulations or the Exchange
Act Rules and Regulations, as applicable. No such documents were
filed with the Commission since the Commission’s close of
business on the business day immediately prior to the date of this
Agreement and prior to the execution of this Agreement, except as
set forth on Schedule III hereto.
(e) The Company does
not own, directly or indirectly, any shares of stock or any other
equity or long-term debt securities of any corporation or have any
equity interest in any corporation, firm, partnership, joint
venture, association or other entity, other than the subsidiaries
listed in Schedule IV hereto (the “Subsidiaries”). Each
of the Company and each of its Subsidiaries is a corporation or
other business entity duly organized, validly existing and in good
standing under the laws of its jurisdiction of incorporation or
formation. The Company and each of its Subsidiaries has full power
and authority to conduct all the activities conducted by it, to own
or lease all the assets owned or leased by it and to conduct its
business as described in the Registration Statement, the Pricing
Prospectus and the Prospectus. Each of the Company and each of its
Subsidiaries is duly licensed or qualified to do business and in
good standing as a foreign corporation or such other business
entity in all jurisdictions in which the nature of the activities
conducted by it or the character of the assets owned or leased by
it makes such license or qualification necessary, except to the
extent that the failure to be so qualified or be in good standing
would not materially and adversely affect the Company and its
Subsidiaries, taken as a whole or their respective condition,
financial or otherwise, or in the earnings, business affairs or
business prospects of the Company or any of the Subsidiaries,
whether or not arising in the ordinary course of business (such
effect is referred to herein as a “Material Adverse
Effect”). All of the outstanding shares of capital stock or
other equity interests of each Subsidiary have been duly authorized
and validly issued and are fully paid and nonassessable, and,
except as set forth in or contemplated by the Registration
Statement, the Pricing Prospectus and the Prospectus, owned by the
Company free and clear of all claims, liens, charges and
encumbrances; there are no securities outstanding that are
convertible into or exercisable or exchangeable for capital stock
of any Subsidiary. The Company and its Subsidiaries are not engaged
in any discussions or a party to any agreement or understanding,
written or oral, regarding the acquisition of an interest in any
corporation, firm, partnership, joint venture, association or other
entity where such discussions, agreements or understandings would
require amendment to the Registration Statement pursuant to
applicable securities laws. Complete and correct copies of the
certificate of incorporation and of the by-laws of the Company and
each of its Subsidiaries and all amendments thereto have been
delivered or made available to the Representatives, and no changes
therein will be made subsequent to the date hereof and prior to the
Closing Date or, if later, the applicable Option Closing
Date.
(f) The Company has
authorized, issued and outstanding capital stock as set forth under
the captions “Prospectus Supplement Summary — The
Offering” and “Description of Securities to be
Registered” in the Pricing Prospectus and the Prospectus as
of the respective dates set forth therein. All of the outstanding
shares of capital stock of the Company (including the Option Shares
to be sold by the Selling Stockholder under this Agreement) have
been duly authorized, validly issued and are fully paid and
nonassessable and were issued in compliance with all applicable
state and federal securities laws; the Firm Shares have been duly
authorized and when issued and paid for as contemplated herein will
be validly issued, fully paid and nonassessable; no preemptive or
similar rights exist with respect to any of the Shares or the issue
and sale thereof. The description of the capital stock of the
Company included or incorporated by reference in the Registration
Statement, the Pricing Prospectus and the Prospectus is complete
and accurate in all respects. Except as set forth in the Pricing
Prospectus and the Prospectus, the Company does not have
outstanding and, at the Closing Date and, if later, the applicable
Option Closing Date, will not have outstanding, any options to
purchase, or any rights or warrants to subscribe for, or any
securities or obligations convertible into, or any contracts or
commitments to issue or sell, any shares of capital stock, or any
such warrants, convertible securities or obligations. No further
approval or authority of stockholders or the Board of Directors of
the Company will be required for the issuance and sale of the Firm
Shares or the transfer and sales of the Option Shares as
contemplated herein. The certificates evidencing the Shares, if
any, are in due and proper legal form and have been duly authorized
for issuance by the Company.
5
(g) The financial
statements and schedules included or incorporated by reference in
the Registration Statement, the Pricing Prospectus or the
Prospectus present fairly, in all material respects, the financial
condition of the Company and its consolidated Subsidiaries as of
the respective dates thereof and the results of operations and cash
flows of the Company and its consolidated Subsidiaries for the
respective periods covered thereby, all in conformity with
generally accepted accounting principles applied on a consistent
basis throughout the entire period involved, except as otherwise
disclosed in the Pricing Prospectus or the Prospectus. No other
financial statements or schedules of the Company are required by
the Act, the Exchange Act, the Exchange Act Rules and Regulations
or the Rules and Regulations to be included in the Registration
Statement, the Pricing Prospectus or the Prospectus. Cherry Bekaert
LLP (the “Accountants”), who have reported on such
financial statements and schedules, are independent accountants
with respect to the Company as required by the Act and the Rules
and Regulations and Rule 3500T of the Public Company Accounting
Oversight Board. The
selected financial data and the summary financial information
included or incorporated by reference in the Registration
Statement, the Pricing Prospectus and the Prospectus present
fairly, in all material respects, the information shown therein and
have been compiled on a basis consistent with the audited financial
statements incorporated by reference in the Registration Statement,
the Pricing Prospectus and the Prospectus. All disclosures
contained in the Registration Statement or the General Disclosure
Package regarding “non-GAAP financial measures” (as
such term is defined in the Rules and Regulations) comply with
Regulation G of the Exchange Act and Item 10 of Regulation S-K
under the Act, to the extent applicable.
(h) Subsequent to the
respective dates as of which information is given in the
Registration Statement, the Pricing Prospectus and the Prospectus
and prior to or on the Closing Date and, if later, the applicable
Option Closing Date, except as set forth in or contemplated by the
Registration Statement, the Pricing Prospectus and the Prospectus,
(i) there has not been any Material Adverse Effect arising for
any reason whatsoever, (ii) neither the Company nor any of
its Subsidiaries has incurred, except in the ordinary course of
business as described in the Pricing Prospectus and the Prospectus,
any material liabilities or obligations, direct or contingent, nor
has the Company or any of its Subsidiaries entered into, except in
the ordinary course of business as described in the Pricing
Prospectus and the Prospectus, any material transactions other than
pursuant to this Agreement and the transactions referred to herein
and (iii) the Company has not paid or declared any dividends
or other distributions of any kind on any class of its capital
stock.
(i) The Company is not,
will not become as a result of the transactions contemplated
hereby, and will not conduct its business in a manner that would
cause it to become, an “investment company” or an
“affiliated person” of, or “promoter” or
“principal underwriter” for, an “investment
company,” as such terms are defined in the Investment Company
Act of 1940, as amended.
(j) Except as set forth
in the Registration Statement, the Pricing Prospectus and the
Prospectus, there are no actions, suits or proceedings pending or,
to the knowledge of the Company, threatened against or affecting
the Company, or any of its Subsidiaries or any of its or their
officers in their capacity as such, before or by any federal or
state court, commission, regulatory body, administrative agency or
other governmental body, domestic or foreign (each, a
“Governmental Entity”), wherein an unfavorable ruling,
decision or finding might have a Material Adverse
Effect.
(k) The Company and
each Subsidiary has, and at the Closing Date and, if later, the
applicable Option Closing Date, will have, performed all the
obligations required to be performed by it, and is not, and at the
Closing Date, and, if later, the applicable Option Closing Date,
will not be, in default, under any contract or other instrument to
which it is a party or by which its property is bound or affected,
which default might reasonably be expected to have a Material
Adverse Effect. To the knowledge of the Company, no other party
under any contract or other instrument to which it or any of its
Subsidiaries is a party is in default in any respect thereunder,
which default might reasonably be expected to have a Material
Adverse Effect. Neither the Company nor any of its Subsidiaries is,
and at the Closing Date and, if later, the applicable Option
Closing Date, will be, in violation of any provision of its
certificate or articles of organization or by-laws or other
organizational documents.
6
(l) No consent,
approval, authorization or order of, or any filing or declaration
with, any Governmental Entity is required for the consummation by
the Company of the transactions on its part contemplated herein,
except such as have been obtained under the Act or the Rules and
Regulations and such as may be required under state securities or
Blue Sky laws or the by-laws and rules of the Financial Industry
Regulatory Authority, Inc. (“FINRA”) in connection with
the purchase and distribution by the Underwriters of the
Shares.
(m) The Company has
full corporate power and authority to enter into this Agreement.
This Agreement has been duly authorized, executed and delivered by
the Company. The performance of this Agreement and the consummation
of the transactions contemplated hereby do not and will not,
whether with or without the giving of notice or passage of time or
both, conflict with or constitute a breach of, or default or
Repayment Event (as defined below) under, or result in the creation
or imposition of any lien, charge or encumbrance upon any
properties or assets of the Company or any of the Subsidiaries
pursuant to any contract, indenture, mortgage, deed of trust, loan
or credit agreement, note, lease or other agreement or instrument
to which the Company or any of the Subsidiaries is a party or by
which it may be bound or to which any of the properties or assets
of the Company or any of the Subsidiaries is subject (except for
such conflicts, breaches, defaults or Repayment Events or liens,
charges or encumbrances that would not reasonably be expected to,
singly or in the aggregate, result in a Material Adverse Effect),
nor will such action result in any violation of (i) the provisions
of the charter or by-laws of the Company or any of the Subsidiaries
or (ii) any law, statute, rule, regulation, judgment, order, writ
or decree of any Governmental Entity, except with respect to clause
(ii), such violations as would not reasonably be expected to,
singly or in the aggregate, result in a Material Adverse Effect. As
used herein, a “Repayment Event” means any event or
condition which gives the holder of any note, debenture or other
evidence of indebtedness (or any person acting on such
holder’s behalf) the right to require the repurchase,
redemption or repayment of all or a portion of such indebtedness by
the Company or any of the Subsidiaries.
(n) The Company and its
Subsidiaries have good and marketable title to all properties and
assets described in the Pricing Prospectus and the Prospectus as
owned by them, free and clear of all liens, charges, encumbrances
or restrictions, except such as are described in the Pricing
Prospectus and the Prospectus or are not, taken as a whole,
material to the business of the Company or its Subsidiaries. The
Company and its Subsidiaries have valid, subsisting and enforceable
leases for the properties described in the Pricing Prospectus and
the Prospectus as leased by them. The Company and its Subsidiaries
own or lease all such properties as are necessary to their
operations as now conducted or as proposed to be conducted, except
where the failure to so own or lease would not have a Material
Adverse Effect.
(o) The Company has not
distributed and will not distribute prior to the later of
(i) the Closing Date or, if later, the applicable Option
Closing Date, and (ii) completion of the distribution of the
Shares, any offering material in connection with the offering and
sale of the Shares other than any preliminary prospectuses, the
Prospectus, the Registration Statement, any Issuer Free Writing
Prospectus listed in Schedule III hereto, and other materials, if
any, permitted by the Act and the Rules and Regulations. Neither
the Company nor any of its directors, officers or controlling
persons has taken, directly or indirectly, any action designed, or
that might reasonably be expected, to cause or result, under the
Act or otherwise, in, or that has constituted, stabilization or
manipulation of the price of any security of the Company to
facilitate the sale or resale of the Shares.
(p) No holder of
securities of the Company has rights to the registration of any
securities of the Company because of the filing of the Registration
Statement, which rights have not been waived by the holder thereof
as of the date hereof.
(q) The Common Stock is
registered under Section 12(b) of the Exchange Act and the Company
will file a Notice of Change in Shares Outstanding with respect to
the Shares in accordance with the requirements of The Nasdaq Stock
Market LLC (“NASDAQ”).
7
(r) Except as would not
reasonably be expected to have a Material Adverse Effect, (i) the
Company and each of the Subsidiaries owns all right, title and
interest in or otherwise have the right to use all patents,
inventions, copyrights, know-how (including trade secrets and other
unpatented and/or unpatentable proprietary or confidential
information, systems or procedures), trademarks, service marks,
trade names and other intellectual property rights (collectively,
“Intellectual Property”) that is necessary for, used or
held for use in, or otherwise exploited in connection with, the
conduct of the business now operated by them and as proposed to be
operated, and (ii) to the Company’s knowledge, neither the
Company nor any of its Subsidiaries is infringing,
misappropriating, diluting or otherwise violating the Intellectual
Property of any third party. Except as set forth in or contemplated
by the Registration Statement, the Pricing Prospectus and the
Prospectus or as would not reasonably be expected to have a
Material Adverse Effect, (i) no action, suit, claim, or other
proceeding is pending, or to the Company’s knowledge, is
threatened, alleging that the Company or any of its Subsidiaries is
infringing, misappropriating, diluting, or otherwise violating the
Intellectual Property of any third party in any respect, (ii) to
the Company’s knowledge, no third party is infringing,
misappropriating, diluting, or otherwise violating the Intellectual
Property of the Company or any of its Subsidiaries in any respect,
and (iii) no action, suit, claim, or other proceeding is pending,
or to the Company’s knowledge, is threatened, challenging the
validity, enforceability, scope, registration, ownership or use of
any Intellectual Property of the Company or any of its Subsidiaries
that is, singly or in the aggregate, necessary to its business
(with the exception of office actions in connection with
applications for the registration or issuance of such Intellectual
Property).
(s) The Company and
each of its Subsidiaries has filed all federal, state, local and
foreign income tax returns that have been required to be filed
through the date hereof and has paid all taxes and assessments
received by it to the extent that such taxes or assessments have
become due, except where such failure to file or pay would not have
a Material Adverse Effect. Neither the Company nor any of its
Subsidiaries has any tax deficiency that has been or, to the
knowledge of the Company, might be asserted or threatened against
it that could have a Material Adverse Effect.
(t) The Company and
each of its Subsidiaries possesses such permits, licenses,
certificates, approvals, clearances, consents and other
authorizations (collectively, “Governmental Licenses”)
issued by the appropriate Governmental Entities necessary to
conduct the business now operated by them, except where the failure
so to possess would not reasonably be expected to, singly or in the
aggregate, result in a Material Adverse Effect. The Company and
each of its Subsidiaries is in compliance with the terms and
conditions of all Governmental Licenses and, to the Company’s
knowledge, no event has occurred which allows, or after notice or
lapse of time would allow, revocation or termination thereof or
result in any other material impairment of the rights of the holder
of any Government License, except where the failure so to comply
would not reasonably be expected to, singly or in the aggregate,
result in a Material Adverse Effect. All of the Governmental
Licenses are valid and in full force and effect. Neither the
Company or any of its Subsidiaries (i) has received notice of any
ongoing claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action from any U.S. or
non-U.S. Governmental Entity or third party alleging that any
product, operation or activity is in violation of any Governmental
Licenses and has no knowledge that any such Governmental Entity or
third party is considering any such claim, litigation, arbitration,
action, suit, investigation or proceeding; (ii) has received notice
that any Governmental Entity has taken, is taking or intends to
take regulatory action, and has no knowledge that any Governmental
Entity is considering such action; or (iii) is a party to any
corporate integrity agreement, deferred prosecution agreement,
monitoring agreement, consent decree, settlement order, or similar
agreements, or has any reporting obligations pursuant to any such
agreement, plan or correction or other remedial measure entered
into with any Governmental Entity.
(u) The Company and
each of its Subsidiaries maintains insurance of the types and in
the amounts generally deemed adequate for its business, including,
but not limited to, insurance covering real and personal property
owned or leased by the Company and its Subsidiaries against theft,
damage, destruction, acts of vandalism and all other risks
customarily insured against, all of which insurance is in full
force and effect.
8
(v) Neither the Company
nor any of its Subsidiaries nor, to the Company’s knowledge,
any director, officer, agent, employee or other person associated
with or acting on behalf of the Company or any of its Subsidiaries
has, directly or indirectly, (i) used any corporate funds for any
unlawful contribution, gift, entertainment or other unlawful
expense relating to political activity, (ii) made any unlawful
payment from corporate funds to any foreign or domestic government
official or employee or foreign or domestic political party or
campaign, (iii) violated any provision of the Foreign Corrupt
Practices Act of 1977, as amended or any applicable law or
regulation implementing the OECD Convention on Combating Bribery of
Foreign Public Officials in International Business Transactions, or
committed an offence under the Xxxxxxx Xxx 0000 of the United
Kingdom or any other applicable anti-bribery or anti-corruption
law, or (iv) made any bribe, illegal rebate, payoff, influence
payment, kickback or other unlawful payment. The Company and its
Subsidiaries have instituted, maintained and enforced, and will
continue to maintain and enforce policies and procedures reasonably
designed to promote and ensure compliance with all applicable
anti-bribery and anti-corruption laws.
(w) The books, records
and accounts of the Company and its Subsidiaries accurately and
fairly reflect, in reasonable detail, the transactions in, and
dispositions of, the assets of, and the results of operations of,
the Company and its Subsidiaries. The Company and each of its
Subsidiaries maintains a system of internal accounting controls
sufficient to provide reasonable assurance that
(i) transactions are executed in accordance with
management’s general or specific authorization,
(ii) transactions are recorded as necessary to permit
preparation of the Company’s consolidated financial
statements in accordance with generally accepted accounting
principles and to maintain asset accountability, (iii) access
to assets is permitted only in accordance with management’s
general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at
reasonable intervals and appropriate action is taken with respect
to any differences. Except as set forth in or contemplated by the
Registration Statement, the Pricing Prospectus and the Prospectus,
the Company’s internal control over financial reporting is
effective and the Company is not aware of any material weaknesses
in its internal control over financial reporting. Since the date of
the latest audited financial statements included or incorporated by
reference in the Pricing Prospectus and the Prospectus, there has
been no change in the Company’s internal control over
financial reporting that has materially affected, or is reasonably
likely to materially affect, the Company’s internal control
over financial reporting.
(x) Except as set forth
in or contemplated by the Registration Statement, the Pricing
Prospectus and the Prospectus, the Company maintains disclosure
controls and procedures (as defined in Rule 13a-15(e) under
the Exchange Act); such disclosure controls and procedures have
been designed to ensure, at a reasonable assurance level, that
material information relating to the Company and its Subsidiaries
is made known to the Company’s principal executive officer
and principal financial officer by others within those entities;
and such disclosure controls and procedures are effective in all
material respects.
(y) There are no
affiliations or associations between any member of FINRA and any of
the Company’s officers, directors, or beneficial owners of
10% or more of any class of the Company’s equity or
equity-linked securities, except as set forth in the Registration
Statement, the Pricing Prospectus and the Prospectus.
(z) The Company is an
“experienced issuer” within the meaning of FINRA Rule
5110(j)(6).
(aa) Neither
the Company nor any of its Subsidiaries nor, to the knowledge of
the Company, any director, officer, agent, employee or affiliate of
the Company or any of its Subsidiaries is an individual or entity
that is, or is owned or controlled by an individual or entity that
is (i) currently subject to any U.S. sanctions administered or
enforced by the U.S. government, (including, without limitation,
the Office of Foreign Assets Control of the U.S. Department of the
Treasury or the U.S. Department of State and including, without
limitation, the designation as a “specially designated
national” or “blocked person”), the United
Nations Security Council, the European Union, Her Majesty’s
Treasury or other relevant sanctions authority (collectively,
“Sanctions”), nor (ii) located, organized or resident
in a country or territory that is the subject or target of
Sanctions, including, without limitation, Crimea, Cuba, Iran, North
Korea, and Syria (each, a “Sanctioned Country”). The
Company will not directly or indirectly use the proceeds of the
offering and sale of the Shares contemplated herein, or lend,
contribute or otherwise make available such proceeds to any
subsidiary, joint venture partner or other person or entity, (i)
for the purpose of financing any activities of or business with any
person that, at the time of such financing, is the subject or
target of Sanctions, (ii) for the purpose of financing any
activities of or business in any Sanctioned Country or (iii) in any
other manner that will result in a violation by any person
(including any person participating in the transaction, whether as
underwriter, advisor, investor or otherwise) of Sanctions. For the
past five years, the Company and its Subsidiaries have not
knowingly engaged in and is not now knowingly engaged in any
dealings or transactions with any person that at the time of the
dealing or transaction is or was the subject or the target of
Sanctions or with any Sanctioned Country.
9
(bb) The
operations of the Company and its Subsidiaries are and have been
conducted at all times in compliance in all material respects with
applicable financial recordkeeping and reporting requirements of
the Currency and Foreign Transactions Reporting Act of 1970, as
amended, the money laundering laws of all applicable jurisdictions,
the rules and regulations thereunder and any related or similar
rules, regulations or guidelines administered or enforced by any
applicable governmental agency (collectively, the “Money
Laundering Laws”) and no action, suit or proceeding by or
before any Governmental Entity or any arbitrator involving the
Company or any of its Subsidiaries with respect to the Money
Laundering Laws is pending or, to the knowledge of the Company,
threatened.
(cc) Except
as would not, individually or in the aggregate, have a Material
Adverse Effect, (i) each of the Company and each of its
Subsidiaries is in compliance with all applicable rules, laws and
regulation relating to pollution, the protection of health or the
environment, and the use, transportation, treatment, storage and
disposal of, or exposure to, hazardous or toxic substances or
wastes, (“Environmental Law”), (ii) none of the Company
nor any of its Subsidiaries has received any written notice from
any Governmental Entity or third party, or otherwise has knowledge,
of an asserted claim under Environmental Laws, and (iii) to the
knowledge of the Company, no facts currently exist that are
reasonably likely to subject the Company or any of its Subsidiaries
to liability under Environmental Laws, including any liability for
remediation of any releases or threatened releases of hazardous or
toxic substances.
(dd) The
statistical, industry-related and market-related data included or
incorporated by reference in the Registration Statement, the
Pricing Prospectus and the Prospectus are based on or derived from
sources the Company reasonably and in good faith believes are
reliable and accurate in all material respects.
(ee) The
Company and each of its Subsidiaries is in compliance in all
material respects with all presently applicable provisions of the
Employee Retirement Income Security Act of 1974, as amended,
including the regulations and published interpretations thereunder
(“ERISA”); no “reportable event” (as
defined in ERISA) has occurred with respect to any “pension
plan” (as defined in ERISA) for which the Company and each of
its Subsidiaries would have any liability; each of the Company and
each of its Subsidiaries has not incurred and does not expect to
incur liability under (i) Title IV of ERISA with respect to
termination of, or withdrawal from, any “pension plan”
or (ii) Sections 412 or 4971 of the Internal Revenue Code of 1986,
as amended, including the regulations and published interpretations
thereunder (the “Code”); and each “pension
plan” for which the Company or any Subsidiary would have any
liability that is intended to be qualified under Section 401(a) of
the Code is so qualified in all material respects and nothing has
occurred, whether by action or by failure to act, which would cause
the loss of such qualification.
(ff) Except
as would not have a Material Adverse Effect, the information
technology assets and equipment, computers, systems, networks,
hardware, software, websites, applications, and databases of the
Company and its Subsidiaries (collectively, “IT
Systems”) are (i) adequate for, and operate and perform as
required in connection with the operation of the business of the
Company and its subsidiaries as currently conducted, and (ii) to
the Company’s knowledge, free and clear of all bugs, errors,
defects, Trojan horses, time bombs, malware and other corruptants.
The Company and its Subsidiaries have implemented and maintained
commercially reasonable controls, policies, procedures, and
safeguards to maintain and protect their material confidential
information and the integrity, continuous operation, redundancy and
security of all IT Systems and data (including all personal,
personally identifiable, sensitive, confidential or regulated data
(“Personal Data”)) used in connection with their
businesses, and, except as described in the Pricing Prospectus and
the Prospectus, there have been no breaches, violations, outages or
known unauthorized uses of or known accesses to the same, except
for those that have been remedied without material cost or
liability or the duty to notify any other person, nor any incidents
under internal review or investigations relating to the same and
except as would not have a Material Adverse Effect. The Company and
its Subsidiaries are presently in compliance with all applicable
laws or statutes and all judgments, orders, rules and regulations
of any court or arbitrator or governmental or regulatory authority,
internal policies and contractual obligations relating to the
privacy and security of IT Systems and Personal Data and to the
protection of such IT Systems and Personal Data from unauthorized
use, access, misappropriation or modification, except where the
failure to be in compliance would not have a Material Adverse
Effect.
10
(gg) No
labor problem or dispute with employees of the Company exists or,
to the knowledge of the Company, is threatened or imminent that
would reasonably be expected to have a Material Adverse Effect; and
the Company is not aware of any existing, threatened or imminent
labor disturbance by the employees of any of its principal
suppliers, manufacturers or contractors that would reasonably be
expected to have a Material Adverse Effect. The Company is not
aware that any key employee or significant group of employees of
the Company plan to terminate employment with the
Company.
(hh) The
interactive data in eXtensible Business Reporting Language, if any,
included or incorporated by reference in the Registration Statement
fairly presents the information called for in all material respects
and have been prepared in accordance with the Commission’s
rules and guidelines applicable thereto to the extent
required.
(ii) Except
as described in the Pricing Prospectus and the Prospectus, there
are no contracts, agreements or understandings between the Company
and any person that would give rise to a valid claim against the
Company or any Underwriter for a brokerage commission,
finder’s fee or other like payment in connection with the
offering of the Shares or any transaction contemplated by this
Agreement, the Pricing Prospectus or the Prospectus.
(jj) There
is and has been no failure on the part of the Company or any of the
Company’s directors or officers, in their capacities as such,
to comply with any provision of the Xxxxxxxx-Xxxxx Act of 2002, as
amended and the rules and regulations promulgated in connection
therewith, including Section 402 related to loans and Sections 302
and 906 related to certifications.
4. Representations,
Warranties and Covenants of the Selling Stockholder.
The Selling
Stockholder represents, warrants and covenants to each Underwriter
that:
(a) All consents,
approvals, authorizations and orders necessary for the execution
and delivery by the Selling Stockholder of this Agreement, and for
the sale and delivery of the Option Shares, have been obtained; and
the Selling Stockholder has full right, power and authority to
enter into this Agreement, to make the representations, warranties
and agreements hereunder and thereunder, and to sell, assign,
transfer and deliver the Option Shares.
(b) Prior to any Option
Closing Date, one or more certificates in negotiable form
representing all of the Option Shares shall be delivered to Issuer
Direct Corporation, the transfer agent for the Shares (the
“Transfer Agent”), together with a stock power with
respect to the Option Shares duly executed by the Selling
Stockholder and delivered by or on behalf of the Selling
Stockholder (the “Stock Power”).
(c) The Selling
Stockholder specifically agrees that the Option Shares represented by the
certificates delivered to the Transfer Agent in accordance with the
foregoing paragraph (b) are for the benefit of and coupled with and
subject to the interests of the Underwriters and the Company, that
the Stock Power is irrevocable, and that the obligations of the
Selling Stockholder hereunder shall not be terminated by operation
of law, whether by the death, disability, incapacity, liquidation
or dissolution of the Selling Stockholder or by the occurrence of
any other event. If the Selling Stockholder or any executor or
trustee for the Selling Stockholder should die or become
incapacitated, or if any other such event should occur, before the
delivery of the Option Shares hereunder, certificates
representing the Option Shares shall be delivered by
or on behalf of the Selling Stockholder in accordance with the
terms and conditions of this Agreement.
(d) This Agreement and
the Stock Power have each been duly
authorized, executed and delivered by the Selling Stockholder and
each such document constitutes a valid and
binding obligation of the Selling Stockholder, enforceable in
accordance with its terms.
(e) No consent,
approval, authorization or order of, or any filing or declaration
with, any court or governmental agency or body is required in
connection with the sale of the Option Shares by the Selling
Stockholder or the consummation by the Selling Stockholder of the
transactions on its part contemplated by this Agreement, except
such as have been obtained under the Act or the Rules and
Regulations and such as may be required under state securities or
Blue Sky laws or the rules of FINRA in connection with the purchase
and distribution by the Underwriters of the Option
Shares.
11
(f) The sale of the
Option Shares and the performance by the Selling Stockholder of
this Agreement and the consummation of the transactions
contemplated hereby and thereby will not result in the creation or
imposition of any lien, charge or encumbrance upon any of the
assets of the Selling Stockholder pursuant to the terms or
provisions of, or result in a breach or violation of any of the
terms or provisions of, or constitute a default under, or give any
party a right to terminate any of its obligations under, or result
in the acceleration of any obligation under, any indenture,
mortgage, deed of trust, voting trust agreement, loan agreement,
bond, debenture, note agreement or other evidence of indebtedness,
lease, contract or other agreement or instrument to which the
Selling Stockholder is a party or by which the Selling Stockholder
or any of its properties is bound or affected, or violate or
conflict with any judgment, ruling, decree, order, statute, rule or
regulation of any court or other governmental agency or body
applicable to the Selling Stockholder or, if the Selling
Stockholder is a corporation, partnership or other entity, the
organizational documents of the Selling Stockholder.
(g) The Selling
Stockholder has, and at each Option Closing Date, will have, good
and marketable title to the Option Shares, free and clear of all
liens, encumbrances, equities or claims whatsoever; and, upon
delivery of the Option Shares and payment therefor pursuant hereto,
good and marketable title to the Option Shares, free and clear of
all liens, encumbrances, equities or claims whatsoever, will be
delivered to the Underwriters.
(h) On each Option
Closing Date, all stock transfer or other taxes (other than income
taxes) that are required to be paid in connection with the
sale and transfer
of the Option Shares to the several Underwriters hereunder will
have been fully paid or provided for by the Selling Stockholder and
all laws imposing such taxes will have been fully complied
with.
(i) Other than as
permitted by the Act and the Rules and Regulations, the Selling
Stockholder has not distributed and will not distribute any
preliminary prospectus, the Prospectus or any other
offering material in connection with the offering and sale of the
Shares. The Selling Stockholder has not taken and will not at any
time take, directly or indirectly, any action designed, or that
might reasonably be expected, to cause or result in, or that will
constitute, stabilization of the price of shares of Common Stock to
facilitate the sale or resale of any of the Shares.
(j) All information
with respect to the Selling Stockholder contained in the
Registration Statement, any preliminary prospectus, the Pricing
Prospectus, the Prospectus or any amendment or supplement thereto
complied or will
comply in all material respects with all applicable requirements of
the Act and the Rules and Regulations and does not and will not
contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to
make the statements therein not misleading.
(k) The Selling
Stockholder has no knowledge of any material fact or condition
not set forth in
the Registration Statement, the Pricing Prospectus or the
Prospectus that has adversely affected, or may adversely affect,
the business, properties, business prospects, condition (financial
or otherwise) or results of operations of the Company and its
Subsidiaries, and the sale of the Shares proposed to be sold by the
Selling Stockholder is not prompted by any such
knowledge.
(l) The Selling
Stockholder has no reason to believe that the
representations and warranties of the Company contained in
Section 3 hereof are not true and correct.
(m) In order to
document the Underwriters’ compliance with the reporting
and withholding provisions of the Tax Equity and Fiscal
Responsibility Act of 1982 with respect to the transactions herein
contemplated, the
Selling Stockholder agrees to deliver to you prior to or at the
Closing Date a properly completed and executed United States
Treasury Department Form W-9 (or other applicable form or
statement specified by Treasury Department regulations in lieu
thereof).
(n) The Selling
Stockholder, directly or indirectly, has not entered into any
commitment, transaction, or other arrangement, including any
prepaid forward contract, 10b5-1 plan or similar agreement, that
transfers or may transfer any of the legal or beneficial ownership
or any of the economic consequences of ownership of Common Stock,
except as has been previously disclosed in writing to the
Representatives.
12
5. Agreements
of the Company and the Selling Stockholder. Each of the Company
and the Selling Stockholder respectively covenants and agrees with
the several Underwriters as follows:
(a) The Company will
not, either prior to the Applicable Time or thereafter during such
period as the Prospectus is required by law to be delivered in
connection with sales of the Shares by an Underwriter or a dealer,
file any amendment or supplement to the Registration Statement, the
Base Prospectus or the Prospectus, unless a copy thereof shall
first have been submitted to the Representatives within a
reasonable period of time prior to the filing thereof and the
Representatives shall not have objected thereto in good
faith.
(b) To the extent
applicable to the offer, sale or distribution of the Shares, the
Company will notify the Representatives promptly, and will confirm
such advice in writing, (i) when any amendment to the
Registration Statement has been filed or becomes effective or any
amendment or supplement to the Prospectus has been filed,
(ii) of any request by the Commission for amendments or
supplements to the Registration Statement or the Prospectus or for
additional information, (iii) of the issuance by the
Commission of any stop order suspending the effectiveness of the
Registration Statement or preventing or suspending the use of the
Base Prospectus, any preliminary prospectus, the Prospectus
Supplement, the Prospectus or any Issuer Free Writing Prospectus or
the initiation of any proceedings for that purpose or the threat
thereof, (iv) of the happening of any event during the period
mentioned in the third sentence of Section 5(e) that in the
judgment of the Company makes any statement made in the
Registration Statement or the Prospectus untrue or that requires
the making of any changes in the Registration Statement or the
Prospectus in order to make the statements therein, in the light of
the circumstances in which they are made, not misleading, and
(v) of receipt by the Company or any representative or
attorney of the Company of any other communication from the
Commission relating to the Company, the Registration Statement, any
preliminary prospectus, the Base Prospectus, the Prospectus
Supplement or the Prospectus. If at any time the Commission shall
issue any order suspending the effectiveness of the Registration
Statement or preventing or suspending the use of the Base
Prospectus, any preliminary prospectus, the Prospectus Supplement,
the Prospectus or any Issuer Free Writing Prospectus, the Company
will make every reasonable effort to obtain the withdrawal of such
order at the earliest possible moment. If the Company has omitted
any information from the Registration Statement pursuant to Rule
430B of the Rules and Regulations, the Company will comply with the
provisions of and make all requisite filings with the Commission
pursuant to said Rule 430B and notify the Representatives promptly
of all such filings. If the Company elects to rely upon Rule 462(b)
under the Act, the Company shall file a registration statement
under Rule 462(b) with the Commission in compliance with Rule
462(b) by 10:00 p.m., Washington, D.C. time, on the date of this
Agreement, and the Company shall at the time of filing either pay
to the Commission the filing fee for such Rule 462(b) registration
statement or give irrevocable instructions for the payment of such
fee pursuant to the Rules and Regulations.
(c) To the extent
applicable to the offer, sale or distribution of the Shares, the
Company will furnish to each Representative, without charge, a copy
of each of the Registration Statement and of any pre- or
post-effective amendment thereto, including financial statements
and schedules, and all exhibits thereto and will furnish to the
Representatives, without charge, for transmittal to each of the
other Underwriters, a copy of the Registration Statement and any
pre- or post-effective amendment thereto, including financial
statements and schedules but without exhibits.
(d) The Company will
comply with all the provisions of any undertakings contained in the
Registration Statement.
13
(e) So long as delivery
of a prospectus by an Underwriter or dealer may be required by the
Act (including in circumstances where such requirement may be
satisfied pursuant to Rule 172 of the Rules and Regulations), the
Company will deliver to each of the Underwriters, without charge,
as many written and electronic copies of each preliminary
prospectus, the Base Prospectus, the Prospectus Supplement, the
Prospectus, each Issuer Free Writing Prospectus or any amendment or
supplement thereto as the Representatives may reasonably request.
The Company consents to the use of each preliminary prospectus, the
Base Prospectus, the Prospectus Supplement, the Prospectus, each
Issuer Free Writing Prospectus and any amendment or supplement
thereto by the Underwriters and by all dealers to whom the Shares
may be sold, both in connection with the offering or sale of the
Shares and for any period of time thereafter during which the
Prospectus is required by law to be delivered in connection
therewith. If during such period of time any event shall occur that
in the judgment of the Company or counsel to the Underwriters
should be set forth in the Prospectus in order to make any
statement therein, in the light of the circumstances under which it
was made, not misleading, or if it is necessary to supplement or
amend the Prospectus to comply with law, the Company will forthwith
prepare and duly file with the Commission an appropriate supplement
or amendment thereto, and will deliver to each of the Underwriters,
without charge, such number of copies of such supplement or
amendment to the Prospectus as the Representatives may reasonably
request. The Company will not file any document under the Exchange
Act or the Exchange Act Rules and Regulations before the
termination of the offering of the Shares by the Underwriters, if
such document would be deemed to be incorporated by reference into
the Prospectus, that is not approved by the Representatives after
reasonable notice thereof. If at any time following issuance of an
Issuer Free Writing Prospectus there occurred or occurs an event or
development as a result of which such Issuer Free Writing
Prospectus conflicted or would conflict with the information
contained in the Registration Statement, the Pricing Prospectus or
the Prospectus or included or would include an untrue statement of
a material fact or omitted or would omit to state a material fact
necessary in order to make the statements therein, in the light of
the circumstances prevailing at that subsequent time, not
misleading, the Company will promptly notify Xxxxxxx & Company,
LLC and, if requested by Xxxxxxx & Company, LLC, will promptly
amend or supplement, at its own expense, such Issuer Free Writing
Prospectus to eliminate or correct such conflict, untrue statement
or omission.
(f) Prior to any public
offering of the Shares, the Company will cooperate with the
Representatives and counsel to the Underwriters in connection with
the registration or qualification of the Shares for offer and sale
under the state or foreign securities or Blue Sky laws of such
jurisdictions as the Representatives may request; provided, that in
no event shall the Company be obligated to qualify to do business
in any jurisdiction where it is not now so qualified or to take any
action that would subject it to general service of process in any
jurisdiction where it is not now so subject or assume any ongoing
reporting obligations to any governmental or other authority in any
jurisdiction.
(g) The Company will,
so long as required under the Rules and Regulations, furnish to its
stockholders after the end of each fiscal year an annual report
(including a balance sheet and statements of income,
stockholders’ equity and cash flow of the Company and its
consolidated Subsidiaries, if any, certified by independent public
accountants) and, after the end of each of the first three quarters
of each fiscal year (beginning with the fiscal quarter ending after
the effective date of the Registration Statement), consolidated
summary financial information of the Company and its Subsidiaries,
if any, for such quarter in reasonable detail, in each case within
the time period required therefor under the Exchange Act and the
Rules and Regulations.
(h) The Company will
make generally available to holders of its securities as soon as
may be practicable, but in no event later than the Availability
Date (as defined below), an earning statement (which need not be
audited but shall be in reasonable detail) covering a period of
12 months commencing after the Effective Date that will
satisfy the provisions of Section 11(a) of the Act (including
Rule 158 of the Rules and Regulations). For the purpose of the
preceding sentence, “Availability Date” means the 45th
day after the end of the fourth fiscal quarter following the fiscal
quarter that includes such Effective Date, except that if such
fourth fiscal quarter is the last quarter of the Company’s
fiscal year, “Availability Date” means the 90th day
after the end of such fourth fiscal quarter.
14
(i) Whether or not
the transactions contemplated by this Agreement are consummated or
this Agreement is terminated, the Company and, unless otherwise
paid by the Company, the Selling Stockholder will pay or reimburse
if paid by the Underwriters, in such proportions as they may agree
upon themselves, all costs and expenses incident to the performance
of the obligations of the Company and the Selling Stockholder under
this Agreement and in connection with the transactions contemplated
hereby, including but not limited to costs and expenses of or
relating to (i) the preparation, printing and filing of the
Registration Statement and exhibits to it, each preliminary
prospectus, the Base Prospectus, the Prospectus Supplement, the
Pricing Prospectus, the Prospectus, any Issuer Free Writing
Prospectus, and any amendment or supplement to any of the
foregoing, (ii) the preparation and delivery of certificates
representing the Shares, if applicable, (iii) furnishing
(including costs of shipping and mailing) such copies of the
Registration Statement, any preliminary prospectus, the Base
Prospectus, the Prospectus Supplement, the Prospectus, and any
Issuer Free Writing Prospectus, and all amendments and supplements
thereto, as may be requested for use in connection with the
offering and sale of the Shares by the Underwriters or by dealers
to whom Shares may be sold, (iv) the listing of the Shares on
the NASDAQ, (v) any filings required to be made in connection
with clearance of the offering of the Shares with FINRA (including
the fees, disbursements and other charges of counsel for the
Underwriters in connection therewith), (vi) the registration
or qualification of the Shares for offer and sale under the state
or foreign securities or Blue Sky laws of such jurisdictions
designated pursuant to Section 5(f) and the preparation,
printing and distribution of any Blue Sky memoranda or foreign
jurisdiction offering wraps or memoranda (including the fees,
disbursements and other charges of counsel for the Underwriters in
connection therewith), (vii) fees, disbursements and other
charges of counsel to the Company (but not those of counsel for the
Underwriters, except as otherwise provided herein) and of the
Accountants, (viii) the transfer agent for the Shares, (ix)
“road show” presentations to prospective purchasers of
the Shares (including any travel expenses of the Company’s
officers, directors and employees in connection with attending or
hosting meetings, but not including travel expenses for employees
of any of the Underwriters, and (x) all other documented
out-of-pocket costs and expenses of the Underwriters incident to
the performance of their obligations hereunder not otherwise
specifically provided for herein, including the fees, disbursements
and other charges of counsel to the Underwriters (in addition to
those set forth in clauses (v) and (vi));provided, however, that in
no event under this clause (x) shall the Company be required to pay
or reimburse if paid by the Underwriters any costs and expenses in
excess of $75,000 in the aggregate. The Underwriters may deem the
Company to be the primary obligor with respect to all costs, fees
and expenses to be paid by the Company and by the Selling
Stockholder. The Selling Stockholder will pay (directly or by
reimbursement) all fees and expenses incident to the performance of
his obligations under this Agreement that are not otherwise
specifically provided for herein, including but not limited to any
fees and expenses of counsel for the Selling Stockholder, and all
expenses and taxes incident to the sale and delivery of the Option
Shares.
(j) The Company will
not at any time, directly or indirectly, take any action designed
or that might reasonably be expected to cause or result in, or that
will constitute, stabilization of the price of the shares of Common
Stock to facilitate the sale or resale of any of the
Shares.
(k) The Company will
apply the net proceeds from the offering and sale of the Shares to
be sold by the Company in the manner set forth in the Pricing
Prospectus and the Prospectus under “Use of
Proceeds.”
(l) During the period
beginning from the date hereof and continuing to and including the
date that is 90 days after the date of the Prospectus, without the
prior written consent of Xxxxxxx & Company, LLC, the Company
will not (1) offer, sell, contract to sell, pledge, grant options,
warrants or rights to purchase, or otherwise dispose of any equity
securities of the Company or any other securities convertible into
or exchangeable for its Common Stock or other equity security or
(2) enter into any swap or other derivatives transaction that
transfers to another, in whole or in part, any of the economic
benefits or risks of ownership of shares of Common Stock, whether
any such transaction described in clause (1) or (2) above is to be
settled by delivery of Common Stock or other securities, in cash or
otherwise, other than (A) the Firm Shares to be sold hereunder, (B)
any options, restricted stock units and other awards granted under
the Company’s stock incentive plans described in the
Registration Statement, the Pricing Prospectus and the Prospectus,
and (C) any shares of Common Stock issued upon the exercise of
options or vesting and settlement of restricted stock units or
other awards granted under such stock incentive plans.
(m) During the period
of 90 days after the date of the Prospectus, the Company will not
file with the Commission or cause to become effective any
registration statement relating to any securities of the Company
without the prior written consent of Xxxxxxx & Company,
LLC.
15
(n) The Company
will cause each of its executive officers and directors to enter
into lock-up agreements with the Representatives to the effect that
they will not, without the prior written consent of Xxxxxxx &
Company, LLC, sell, contract to sell or otherwise dispose of any
shares of Common Stock or rights to acquire such shares according
to the terms set forth in Schedule V hereto.
6. Further
Agreements
(a) The
Company represents and agrees that, without the prior written
consent of the Representatives, and each Underwriter represents and
agrees that, without the prior written consent of the Company and
the Representatives, it has not made and will not make any offer
relating to the Shares that would constitute a “free writing
prospectus” as defined in Rule 405 of the Rules and
Regulations. Any such Free Writing Prospectus the use of which has
been consented to by the Company and the Representatives is listed
on Schedule III and herein called a “Permitted Free Writing
Prospectus.”
(b) The Company agrees
that it has treated and will treat, as the case may be, each
Permitted Free Writing Prospectus as an Issuer Free Writing
Prospectus and that it has complied and will comply, as the case
may be, with the requirements of Rules 164 and 433 of the Rules and
Regulations applicable to any Permitted Free Writing Prospectus,
including timely Commission filing where required, record keeping
and legending.
7. Conditions
of the Obligations of the Underwriters. The obligations of
each Underwriter hereunder are subject to the following
conditions:
(a) All filings
required by Rule 424 and Rule 430A of the Rules and Regulations
shall have been made. If the Company has elected to rely upon Rule
462(b), the registration statement filed under Rule 462(b) shall
have become effective by 10:00 p.m., Washington, D.C. time, on the
date of this Agreement.
(b) (i) No stop
order suspending the effectiveness of the Registration Statement or
preventing or suspending the use of the Base Prospectus, any
preliminary prospectus, the Prospectus Supplement, the Prospectus
or any Issuer Free Writing Prospectus shall have been issued and no
proceedings for that purpose shall be pending or threatened by the
Commission, (ii) no order suspending the effectiveness of the
Registration Statement or the qualification or registration of the
Shares under the securities or Blue Sky laws of any jurisdiction
shall be in effect and no proceeding for such purpose shall be
pending before or threatened or contemplated by the Commission or
the authorities of any such jurisdiction, (iii) any request
for additional information on the part of the staff of the
Commission or any such authorities shall have been complied with to
the satisfaction of the staff of the Commission or such
authorities, (iv) after the date hereof no amendment or
supplement to the Registration Statement, the Prospectus or the
Pricing Prospectus shall have been filed unless a copy thereof was
first submitted to the Representatives and the Representatives do
not object thereto in good faith, and (v) the Representatives
shall have received certificates, dated the Closing Date and, if
later, the applicable Option Closing Date and signed by the Chief
Executive Officer and the Chief Financial Officer of the Company
(who may, as to proceedings threatened, rely upon the best of their
information and belief), to the effect of clauses (i), (ii)
and (iii) of this paragraph.
(c) Since the
respective dates as of which information is given in the
Registration Statement and the Pricing Prospectus, (i) there
shall not have been a material adverse change in the general
affairs, business, business prospects, properties, management,
condition (financial or otherwise) or results of operations of the
Company or any of its Subsidiaries, whether or not arising from
transactions in the ordinary course of business, in each case other
than as described in or contemplated by the Registration Statement
and the Pricing Prospectus, and (ii) neither the Company nor
any of its Subsidiaries shall have sustained any material loss or
interference with its business or properties from fire, explosion,
flood or other casualty, whether or not covered by insurance, or
from any labor dispute or any court or legislative or other
governmental action, order or decree, which is not described in the
Registration Statement and the Pricing Prospectus, if in the
judgment of the Representatives any such development makes it
impracticable or inadvisable to consummate the sale and delivery of
the Shares by the Underwriters at the initial public offering
price.
16
(d) Since the
respective dates as of which information is given in the
Registration Statement and the Pricing Prospectus, there shall have
been no litigation or other proceeding instituted against the
Company, any of its Subsidiaries, or any of its or their officers
or directors in their capacities as such, before or by any federal,
state or local court, commission, regulatory body, administrative
agency or other governmental body, domestic or foreign, in which
litigation or proceeding an unfavorable ruling, decision or finding
would, in the judgment of the Representatives, have a Material
Adverse Effect or if, in the judgment of the Representatives, any
such development makes it impracticable or inadvisable to
consummate the sale and delivery of the Shares by the Underwriters
at the initial public offering price.
(e) Each of the
representations and warranties of the Company and the Selling
Stockholder contained herein shall be true and correct in all
respects (in the case of any representation and warranty containing
a materiality or Material Adverse Effect qualification) or in all
material respects (in the case of any other representation and
warranty) at the Closing Date and, with respect to the Option
Shares, at the applicable Option Closing Date, and all covenants
and agreements contained herein to be performed on the part of the
Company or the Selling Stockholder and all conditions contained
herein to be fulfilled or complied with by the Company or the
Selling Stockholder at or prior to the Closing Date and, with
respect to the Option Shares, at or prior to the applicable Option
Closing Date, shall have been duly performed, fulfilled or complied
with.
(f) The Representatives
shall have received an opinion and a negative assurance letter,
dated the Closing Date and, with respect to the Option Shares, the
applicable Option Closing Date, satisfactory in form and substance
to the Representatives and counsel for the Underwriters from
Xxxxxxx & Xxxx, S.C., counsel to the Company.
(g) The representatives
shall have received an opinion and negative assurance letter, dated
the Closing Date or the applicable Option Closing Date, as the case
may be, from Pillsbury Xxxxxxxx Xxxx Xxxxxxx LLP, counsel to the
Underwriters, with respect to the Registration Statement, the
Prospectus and this Agreement, which opinion and negative assurance
letter shall be satisfactory in all respects to the
Representatives.
(h) Concurrently with
the execution and delivery of this Agreement, the Accountants shall
have furnished to the Representatives a letter, dated the date of
its delivery, addressed to the Representatives and in form and
substance satisfactory to the Representatives, confirming that they
are independent accountants with respect to the Company and its
Subsidiaries as required by the Act and the Exchange Act and the
Rules and Regulations and with respect to certain financial and
other statistical and numerical information contained or
incorporated by reference in the Registration Statement, the
Prospectus and the General Disclosure Package. At the Closing Date
and, as to the Option Shares, the applicable Option Closing Date,
the Accountants shall have furnished to the Representatives a
letter, dated the date of its delivery, which shall confirm, on the
basis of a review in accordance with the procedures set forth in
the letter from the Accountants, that nothing has come to their
attention during the period from the date of the letter referred to
in the prior sentence to a date (specified in the letter) not more
than three days prior to the Closing Date or the applicable Option
Closing Date, as the case may be, which would require any change in
their letter dated the date hereof if it were required to be dated
and delivered at the Closing Date or the applicable Option Closing
Date, as the case may be.
(i) At the Closing Date
and, as to the Option Shares, the applicable Option Closing Date,
there shall be furnished to the Representatives a certificate,
dated the date of its delivery, signed by each of the Chief
Executive Officer and the Chief Financial Officer of the Company,
in form and substance satisfactory to the Representatives, to the
effect that:
(i) Each signer of such
certificate has carefully examined the Registration Statement, the
Prospectus and the General Disclosure Package (including any
documents filed under the Exchange Act and deemed to be
incorporated by reference into the Pricing Prospectus and the
Prospectus) and (A) as of the date of such certificate, such
documents are true and correct in all material respects and do not
omit to state a material fact required to be stated therein or
necessary in order to make the statements therein not untrue or
misleading and (B) in the case of the certificate delivered at
the Closing Date and the applicable Option Closing Date, since the
Effective Date no event has occurred as a result of which it is
necessary to amend or supplement the Prospectus in order to make
the statements therein not untrue or misleading.
17
(ii) Each
of the representations and warranties of the Company contained in
this Agreement were, when originally made, and are, at the time
such certificate is delivered, true and correct in all respects (in
the case of any representation and warranty containing a
materiality or Material Adverse Effect qualification) or in all
material respects (in the case of any other representation and
warranty).
(iii) Each
of the covenants required to be performed by the Company herein on
or prior to the date of such certificate has been duly, timely and
fully performed and each condition herein required to be satisfied
or fulfilled on or prior to the date of such certificate has been
duly, timely and fully satisfied or fulfilled.
(j) At the Option
Closing Date, there shall be furnished to the Representatives (i) a
certificate, dated the date of its delivery, signed by the Selling
Stockholder, in form and substance satisfactory to the
Representatives, to the effect that the representations and
warranties of the Selling Stockholder contained herein are true and
correct in all material respects on and as of the date of such
certificate as if made on and as of the date of such certificate,
and each of the covenants and conditions required herein to be
performed or complied with by the Selling Stockholder on or prior
to the date of such certificate has been duly, timely and fully
performed or complied with and (ii) an opinion, dated the Option
Closing Date, satisfactory in form and substance to the
Representatives and counsel for the Underwriters from Xxxxxxx &
Xxxx, S.C., counsel to the Selling Stockholder.
(k) On or prior to the
Closing Date, the Representatives shall have received the executed
agreements referred to in Section 55(n).
(l) The Shares shall be
qualified for sale in such jurisdictions as the Representatives may
reasonably request and each such qualification shall be in
effect and not subject to any stop order or other proceeding on the
Closing Date or the applicable Option Closing Date.
(m) The Company and the Selling
Stockholder shall have furnished to the Representatives such
further certificates and documents, in addition to those
specifically mentioned herein, as the Representatives may have
reasonably requested as to the accuracy and completeness at
the Closing Date and the applicable Option Closing Date of any
statement in the Registration Statement, the Prospectus or the
General Disclosure Package, as to the accuracy at the Closing Date
and the applicable Option Closing Date of the representations and
warranties of the Company and the Selling Stockholder herein, as to
the performance by the Company and the Selling Stockholder of their
respective obligations hereunder, or as to the fulfillment of the
conditions concurrent and precedent to the obligations hereunder of
the Representatives.
8. Indemnification.
(a) The
Company and the Selling Stockholder, jointly and severally, will
indemnify and hold harmless each Underwriter, the partners,
members, directors, officers, employees, agents and affiliates of
each Underwriter and each person, if any, who controls each
Underwriter within the meaning of Section 15 of the Act or
Section 20 of the Exchange Act, from and against any and all
losses, claims, liabilities, expenses and damages (including any
and all investigative, legal and other expenses reasonably incurred
in connection with, and any amount paid in settlement of, any
action, suit or proceeding or any claim asserted), to which they,
or any of them, may become subject under the Act, the Exchange Act
or other federal or state statutory law or regulation, at common
law or otherwise, insofar as such losses, claims, liabilities,
expenses or damages arise out of or are based on any untrue
statement or alleged untrue statement of a material fact contained
in the Registration Statement, any preliminary prospectus, the Base
Prospectus, the Pricing Prospectus, the Prospectus, or any
amendment or supplement thereto, any Issuer Free Writing
Prospectus, any “road show” as defined in Rule 433(h)
under the Act (“road show”), or any “issuer
information” filed or required to be filed pursuant to Rule
433(d) of the Rules and Regulations, or arise out of the omission
or alleged omission to state therein a material fact required to be
stated in it or necessary to make the statements in it not
misleading in the light of the circumstances in which they were
made, or arise out of or are based in whole or in part on any
inaccuracy in the representations and warranties of the Company or
the Selling Stockholder contained herein or any failure of the
Company or the Selling Stockholder to perform its or their
obligations hereunder or under law in connection with the
transactions contemplated hereby; provided, however, that (i) the Company and the
Selling Stockholder will not be liable to the extent that such
loss, claim, liability, expense or damage arises from the sale of
the Shares in the public offering to any person by an Underwriter
and is based on an untrue statement or omission or alleged untrue
statement or omission made in reliance on and in conformity with
information relating to any Underwriter furnished in writing to the
Company by the Representatives, on behalf of any Underwriter,
expressly for inclusion in the Registration Statement, any
preliminary prospectus, the Base Prospectus, the Pricing
Prospectus, the Prospectus, or any amendment or supplement thereto,
any Issuer Free Writing Prospectus, any road show, or any
“issuer information” filed or required to be filed
pursuant to Rule 433(d) of the Rules and Regulations; and (ii) the
liability of the Selling Stockholder under this Section 8(a) shall
not exceed the product of the purchase price for each Share set
forth in Section 1(a) hereof multiplied by the number of Option
Shares sold by the Selling Stockholder hereunder. The Company and
the Selling Stockholder acknowledge that the Underwriter
Information constitutes the only information relating to any
Underwriter furnished in writing to the Company by the
Representatives on behalf of the Underwriters expressly for
inclusion in the Registration Statement, any preliminary
prospectus, the Base Prospectus, the Pricing Prospectus, the
Prospectus, or any amendment or supplement thereto, any Issuer Free
Writing Prospectus, any road show, any “issuer
information” filed or required to be filed pursuant to Rule
433(d) of the Rules and Regulations. This indemnity agreement will
be in addition to any liability that the Company and the Selling
Stockholder might otherwise have.
18
(b) Each Underwriter,
severally and not jointly, will indemnify and hold harmless the
Company, each director of the Company, each officer of the Company
who signs the Registration Statement, each person, if any, who
controls the Company within the meaning of Section 15 of the
Act or Section 20 of the Exchange Act, and the Selling
Stockholder to the same extent as the foregoing indemnity from the
Company and the Selling Stockholder to each Underwriter, as set
forth in Section 8(a), but only insofar as losses, claims,
liabilities, expenses or damages arise out of or are based on any
untrue statement or omission or alleged untrue statement or
omission made in reliance on and in conformity with information
relating to any Underwriter furnished in writing to the Company by
the Representatives, on behalf of such Underwriter, expressly for
inclusion in the Registration Statement, any preliminary
prospectus, the Base Prospectus, the Pricing Prospectus, the
Prospectus, or any amendment or supplement thereto, any Issuer Free
Writing Prospectus, any road show, or any “issuer
information” filed or required to be filed pursuant to Rule
433(d) of the Rules and Regulations. The Company and the Selling
Stockholder acknowledge that the Underwriter Information
constitutes the only information relating to any Underwriter
furnished in writing to the Company by the Representatives on
behalf of the Underwriters expressly for inclusion in the
Registration Statement, any preliminary prospectus, the Base
Prospectus, the Pricing Prospectus, the Prospectus, or any
amendment or supplement thereto, any Issuer Free Writing
Prospectus, and road show, or, or any “issuer
information” filed or required to be filed pursuant to Rule
433(d) of the Rules and Regulations. This indemnity will be in
addition to any liability that each Underwriter might otherwise
have.
(c) Any party that
proposes to assert the right to be indemnified under this
Section 8 shall, promptly after receipt of notice of
commencement of any action against such party in respect of which a
claim is to be made against an indemnifying party or parties under
this Section 8, notify each such indemnifying party in writing
of the commencement of such action, enclosing with such notice a
copy of all papers served, but the omission so to notify such
indemnifying party will not relieve it from any liability that it
may have to any indemnified party under the foregoing provisions of
this Section 8 unless, and only to the extent that, such omission
results in the loss of substantive rights or defenses by the
indemnifying party. If any such action is brought against any
indemnified party and it notifies the indemnifying party of its
commencement, the indemnifying party will be entitled to
participate in and, to the extent that it elects by delivering
written notice to the indemnified party promptly after receiving
notice of the commencement of the action from the indemnified
party, jointly with any other indemnifying party similarly
notified, to assume the defense of the action, with counsel
reasonably satisfactory to the indemnified party. After notice from
the indemnifying party to the indemnified party of its election to
assume the defense, the indemnifying party will not be liable to
the indemnified party for any legal or other expenses except as
provided below and except for the reasonable costs of investigation
incurred by the indemnified party in connection with the defense.
The indemnified party will have the right to employ its own counsel
in any such action, but the fees, expenses and other charges of
such counsel will be at the expense of such indemnified party
unless (i) the employment of counsel by the indemnified party
has been authorized in writing by the indemnifying party,
(ii) the indemnified party has reasonably concluded (based on
advice of counsel) that there may be legal defenses available to it
or other indemnified parties that are different from or in addition
to those available to the indemnifying party, (iii) a conflict
or potential conflict exists (based on advice of counsel to the
indemnified party) between the indemnified party and the
indemnifying party (in which case the indemnifying party will not
have the right to direct the defense of such action on behalf of
the indemnified party), or (iv) the indemnifying party has not
in fact employed counsel reasonably satisfactory to the indemnified
party to assume the defense of such action within a reasonable time
after receiving notice of the commencement of the action, in each
of which cases the reasonable fees, disbursements and other charges
of counsel will be at the expense of the indemnifying party or
parties. It is understood that the indemnifying party or parties
shall not, in connection with any proceeding or related proceedings
in the same jurisdiction, be liable for the reasonable fees,
disbursements and other charges of more than one separate firm
admitted to practice in such jurisdiction at any one time for all
such indemnified party or parties. All such fees, disbursements and
other charges will be reimbursed by the indemnifying party promptly
as they are incurred. No indemnifying party shall, without the
prior written consent of the indemnified party, effect any
settlement of any pending or threatened action in respect of which
any indemnified party is or could have been a party and indemnity
could have been sought hereunder by such indemnified party unless
such settlement (i) includes an unconditional release of such
indemnified party from all liability on any claims that are the
subject matter of such action and (ii) does not include a statement
as to, or an admission of, fault, culpability or a failure to act
by or on behalf of an indemnified party. An indemnifying party will
not be liable for any settlement of any action or claim effected
without its written consent (which consent will not be unreasonably
withheld or delayed).
19
(d) If the
indemnification provided for in this Section 8 is applicable
in accordance with its terms but for any reason is held to be
unavailable to or insufficient to hold harmless an indemnified
party under paragraphs (a), (b) and (c) of this Section 8 in
respect of any losses, claims, liabilities, expenses and damages
referred to therein, then each applicable indemnifying party, in
lieu of indemnifying such indemnified party, shall contribute to
the amount paid or payable (including any investigative, legal and
other expenses reasonably incurred in connection with, and any
amount paid in settlement of, any action, suit or proceeding or any
claim asserted, but after deducting any contribution received by
the Company or the Selling Stockholder from persons other than the
Underwriters, such as persons who control the Company within the
meaning of the Act, officers of the Company who signed the
Registration Statement and directors of the Company, who also may
be liable for contribution) by such indemnified party as a result
of such losses, claims, liabilities, expenses and damages in such
proportion as shall be appropriate to reflect the relative benefits
received by the Company and the Selling Stockholder, on the one
hand, and the Underwriters, on the other hand. The relative
benefits received by the Company and the Selling Stockholder, on
the one hand, and the Underwriters, on the other hand, shall be
deemed to be in the same proportion as the total net proceeds from
the offering (before deducting expenses) received by the Company
and the Selling Stockholder bear to the total underwriting
discount received by
the Underwriters, in each case as set forth in the table on the
cover page of the Prospectus. If, but only if, the allocation
provided by the foregoing sentence is not permitted by applicable
law, the allocation of contribution shall be made in such
proportion as is appropriate to reflect not only the relative
benefits referred to in the foregoing sentence but also the
relative fault of the Company and the Selling Stockholder, on the
one hand, and the Underwriters, on the other hand, with respect to
the statements or omissions that resulted in such loss, claim,
liability, expense or damage, or action in respect thereof, as well
as any other relevant equitable considerations with respect to such
offering. Such relative fault shall be determined by reference to
whether the untrue or alleged untrue statement of a material fact
or omission or alleged omission to state a material fact relates to
information supplied by the Company, the Selling Stockholder or the
Representatives on behalf of the Underwriters, the intent of the
parties and their relative knowledge, access to information and
opportunity to correct or prevent such statement or omission. The
Company, the Selling Stockholder and the Underwriters agree that it
would not be just and equitable if contributions pursuant to this
Section 8(d) were to be determined by pro rata allocation (even if
the Underwriters were treated as one entity for such purpose) or by
any other method of allocation that does not take into account the
equitable considerations referred to herein. The amount paid or
payable by an indemnified party as a result of the loss claim,
liability, expense or damage, or action in respect thereof,
referred to above in this Section 8(d) shall be deemed to
include, for purposes of this Section 8(d), any legal or other
expenses reasonably incurred by such indemnified party in
connection with investigating or defending any such action or
claim. Notwithstanding the provisions of this Section 8(d), no
Underwriter shall be required to contribute any amount in excess of
the underwriting discount received by
it, the Selling Stockholder shall not be required to contribute any
amount in excess of the product of the purchase price for each
Share set forth in Section 1(a) hereof multiplied by the number of
Option Shares sold by the Selling Stockholder hereunder, and no
person found guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Act) will be entitled to
contribution from any person who was not guilty of such fraudulent
misrepresentation. The Underwriters’ obligations to
contribute as provided in this Section 8(d) are several in
proportion to their respective underwriting obligations and not
joint. For purposes of this Section 8(d), any person who controls a
party to this Agreement within the meaning of the Act will have the
same rights to contribution as that party, and each officer of the
Company who signed the Registration Statement will have the same
rights to contribution as the Company, subject in each case to the
provisions hereof. Any party entitled to contribution, promptly
after receipt of notice of commencement of any action against any
such party in respect of which a claim for contribution may be made
under this Section 8(d), will notify any such party or parties from
whom contribution may be sought, but the omission so to notify will
not relieve the party or parties from whom contribution may be
sought from any other obligation it or they may have under this
Section 8(d). No party will be liable for contribution with respect
to any action or claim settled without its written consent (which
consent will not be unreasonably withheld).
(e) The indemnity and
contribution agreements contained in this Section 8 and the
representations and warranties of the Company and the Selling
Stockholder contained in this Agreement shall remain operative and
in full force and effect regardless of (i) any investigation
made by or on behalf of the Underwriters, (ii) acceptance of
any of the Shares and payment therefor, or (iii) any
termination of this Agreement. The provisions of this Section 8
shall not affect any agreement between the Company and the Selling
Stockholder with respect to indemnification or
contribution.
20
9. Reimbursement
of Certain Expenses. In addition to its
other obligations under Section 8(a) of this Agreement, the Company
hereby agrees to reimburse the Underwriters on a quarterly basis
for all reasonable legal and other expenses incurred in connection
with investigating or defending any claim, action, investigation,
inquiry or other proceeding arising out of or based upon, in whole
or in part, any statement or omission or alleged statement or
omission, or any inaccuracy in the representations and warranties
of the Company or the Selling Stockholder contained herein or
failure of the Company or the Selling Stockholder to perform its or
their respective obligations hereunder or under law, all as
described in Section 8(a), notwithstanding the absence of a
judicial determination as to the propriety and enforceability of
the obligations under this Section 8 and the possibility that
such payment might later be held to be improper; provided, however, that, to the extent
any such payment is ultimately held to be improper, the persons
receiving such payments shall promptly refund them.
10. Termination.
The obligations of
the several Underwriters under this Agreement may be terminated at
any time on or prior to the Closing Date (or, with respect to the
Option Shares, on or prior to the applicable Option Closing Date),
by notice to the Company and the Selling Stockholder from the
Representatives, without liability on the part of any Underwriter
to the Company or the Selling Stockholder if, prior to delivery and
payment for the Firm Shares or Option Shares, as the case may be,
in the sole judgment of the Representatives, (i) trading in
any of the equity securities of the Company shall have been
suspended or limited by the Commission or by The Nasdaq Stock
Market, (ii) trading in securities generally on The Nasdaq
Stock Market shall
have been suspended or limited or minimum or maximum prices shall
have been generally established on such exchange, or additional
material governmental restrictions, not in force on the date of
this Agreement, shall have been imposed upon trading in securities
generally by such exchange, by order of the Commission or any court
or other governmental authority, or by The Nasdaq Stock Market,
(iii) a general banking moratorium shall have been declared by
either federal or New York State authorities or any material
disruption of the securities settlement or clearance services in
the United States shall have occurred, or (iv) any material
adverse change in the financial or securities markets in the United
States or in political, financial or economic conditions in the
United States, any outbreak or material escalation of hostilities
involving the United States, a declaration of a national emergency
or war by the United States, or other calamity or crisis, either
within or outside the United States, shall have occurred, the effect of
which is such as to make it, in the sole judgment of the
Representatives, impracticable or inadvisable to proceed with
completion of the public offering or the delivery of and payment
for the Shares.
If this
Agreement is terminated pursuant to Section 11 hereof, neither
the Company nor the Selling Stockholder shall be under any
liability to any Underwriter except as provided in Sections 5(i), 8
and 9 hereof; but, if for any other reason the purchase of the
Shares by the Underwriters is not consummated or if for any reason
the Company shall be unable to perform its obligations hereunder,
the Company and the Selling Stockholder will reimburse the
Underwriters for all out-of-pocket expenses (including the fees,
disbursements and other charges of counsel to the Underwriters)
incurred by the Underwriters in connection with the offering of the
Shares.
11. Substitution
of Underwriters. If any one or more
of the Underwriters shall fail or refuse to purchase any of the
Firm Shares that it or they have agreed to purchase hereunder, and
the aggregate number of Firm Shares that such defaulting
Underwriter or Underwriters agreed but failed or refused to
purchase is not more than one-tenth of the aggregate number of Firm
Shares, the other Underwriters shall be obligated, severally and
not jointly, to purchase the Firm Shares that such defaulting
Underwriter or Underwriters agreed but failed or refused to
purchase, in the proportions which the number of Firm Shares that
they have respectively agreed to purchase pursuant to
Section 1 bears to the aggregate number of Firm Shares which
all such non-defaulting Underwriters have so agreed to purchase, or
in such other proportions as the Representatives may specify;
provided that in no event shall the maximum number of Firm Shares
that any Underwriter has become obligated to purchase pursuant to
Section 1 be increased pursuant to this Section 11 by
more than one-ninth of such number of Firm Shares without the prior
written consent of such Underwriter. In any such case either the
Representatives or the Company shall have the right to postpone the
Closing Date, but in no event for longer than seven days, in order
that the required changes, if any, in the Registration Statement
and the Prospectus or in any other documents or arrangements may be
effected. If any Underwriter or Underwriters shall fail or refuse
to purchase any Firm Shares that it or they agreed to purchase
hereunder and the aggregate number of Firm Shares which such
defaulting Underwriter or Underwriters agreed but failed or refused
to purchase exceeds one-tenth of the aggregate number of the Firm
Shares and arrangements satisfactory to the Representatives and the
Company for the purchase of such Firm Shares are not made within
48 hours after such default, this Agreement will terminate
without liability on the part of any non-defaulting Underwriter,
the Selling Stockholder or the Company for the purchase or sale of
any Shares under this Agreement. Any action taken pursuant to this
Section 11 shall not relieve any defaulting Underwriter from
liability in respect of any default of such Underwriter under this
Agreement.
21
12. No
Fiduciary Relationship. Notwithstanding any
preexisting relationship, advisory or otherwise, between the
parties or any oral representations or assurances previously or
subsequently made by the Underwriters, the Company and the Selling
Stockholder acknowledges and agrees that (i) the purchase and
sale of the Shares pursuant to this Agreement (including the
determination of the terms of the offering of the Shares) is an
arm’s-length commercial transaction between the Company and
the Selling Stockholder, on the one hand, and the several
Underwriters, on the other hand, (ii) in connection therewith
and with the process leading to such transaction, each Underwriter
is acting solely as a principal and not the agent or fiduciary of
the Company or the Selling Stockholder, (iii) no Underwriter
has assumed an advisory or fiduciary responsibility in favor of the
Company or the Selling Stockholder with respect to the offering
contemplated hereby or the process leading thereto (irrespective of
whether such Underwriter has advised or is currently advising the
Company or the Selling Stockholder on other matters) or any other
obligation to the Company or the Selling Stockholder except the
obligations expressly set forth in this Agreement, (iv) the
Underwriters and their respective affiliates may be engaged in a
broad range of transactions that involve interests that differ from
those of the Company or the Selling Stockholder and have no
obligation to disclose or account to the Company or the Selling
Stockholder for any of such differing interests, and (v) the
Company and the Selling Stockholder has consulted its own legal,
tax, accounting and financial advisors to the extent it deemed
appropriate. The Company and the Selling Stockholder hereby
agrees that it will not claim that the Underwriters, or any of
them, have rendered advisory services of any nature or respect, or
owe a fiduciary or similar duty to the Company or the Selling
Stockholder, in connection with such transaction or the process
leading thereto.
13. Miscellaneous.
Notice given
pursuant to any of the provisions of this Agreement shall be in
writing and, unless otherwise specified, shall delivered or sent by
mail, telex, facsimile transmission or e-mail (a) if to the
Company or the Selling Stockholder, at the office of the Company,
0000 Xxxxxxxxxxx Xxxxxx Xxxxxx, Xxxxx 000, Xxxxxxxxxxx, Xxxxxxx
00000, Attention: Chief Financial Officer, with a copy to X.X.
Xxxxxxx, Esq., Xxxxxxx & Xxxx, S.C., 000 Xxxx Xxxxxxxx Xxxxxx,
Xxxxx 0000 Xxxxxxxxx, Xxxxxxxxx 00000 or (b) if to the
Underwriters, to the Representatives at the offices of
Xxxxxxx & Company, LLC, 000 Xxxx Xxxxxx, 00xx Xxxxx, Xxx
Xxxx, Xxx Xxxx 00000, Attention: Corporate Finance Department and
Lake Street Capital Markets, LLC, 000 Xxxxxx Xxxxxx Xxxxx, Xxxxx
000, Xxxxxxxxxxx, Xxxxxxxxx 00000 Attention: Syndicate Department,
Email: xxxxxxxxx@xxxxxxxxxxxx.xxx with a copy to Xxxxxxx X. Xxxx,
Esq., Pillsbury Xxxxxxxx Xxxx Xxxxxxx LLP, Four Xxxxxxxxxxx Xxxxxx,
00xx Xxxxx, Xxx Xxxxxxxxx, Xxxxxxxxxx 00000. Any such notice shall
be effective only upon receipt. Any notice under Section 10 or
11 may be made by facsimile transmission or telephone, but if so
made shall be subsequently confirmed in writing.
This
Agreement has been and is made solely for the benefit of the
several Underwriters, the Company, the Selling Stockholder and the
controlling persons, directors and officers referred to in Section
8, and their respective successors and assigns, and no other person
shall acquire or have any right under or by virtue of this
Agreement. The term “successors and assigns” as used in
this Agreement shall not include a purchaser, as such purchaser, of
Shares from any of the several Underwriters.
Any
action required or permitted to be made by the Representatives
under this Agreement may be taken by them jointly or by Xxxxxxx
& Company, LLC.
This
Agreement shall be governed by and construed in accordance with the
laws of the State of New York applicable to contracts made and to
be performed entirely within such State.
This
Agreement may be signed in two or more counterparts with the same
effect as if the signatures thereto and hereto were upon the same
instrument.
In case
any provision in this Agreement shall be invalid, illegal or
unenforceable, the validity, legality and enforceability of the
remaining provisions shall not in any way be affected or impaired
thereby.
Each
of the Company, the Selling Stockholder and the Underwriters hereby
waives any right it may have to a trial by jury in respect of any
claim based upon or arising out of this Agreement or the
transactions contemplated hereby.
22
Please
confirm that the foregoing correctly sets forth the agreement among
the Company, the Selling Stockholder and the several
Underwriters.
|
Very truly
yours,
|
|
|
|
|
|
|
|
By:
|
/s/ Xxxxx
Xxxxxxx
|
|
|
Name: Xxxxx
Xxxxxxx
|
|
|
|
|
Title: Chief Financial Officer |
|
|
Selling Stockholder
|
|
|
|
|
|
|
|
By:
|
/s/ Xxxxxxx
Xxxxxxx
|
|
|
Name: Xxxxxxx
Xxxxxxx
|
|
|
|
Confirmed as of the
date first
above
mentioned:
Xxxxxxx & Company, LLC
Acting
on behalf of itself
and as
a Representative of
the
other several Underwriters
named
in Schedule I hereto.
By:
Xxxxxxx & Company, LLC
By:
/s/ Xxxxxxx Xxxx
Name:
Xxxxxxx Xxxx
Title:
Managing Director
Lake Street Capital Markets, LLC
Acting
on behalf of itself
and as
a Representative of
the
other several Underwriters
named
in Schedule I hereto.
By:
Lake Street Capital Markets, LLC
By:
/s/ Xxxxxxx Xxxxxxx
Name:
Xxxxxxx Xxxxxxx
Title:
Head of Investment Banking
SCHEDULE I
UNDERWRITERS
Underwriters
|
Number of Firm Shares
to be Purchased
|
Xxxxxxx &
Company,
LLC
|
000,000
|
Xxxx Xxxxxx Xxxxxxx
Xxxxxxx,
LLC
|
250,000
|
|
|
|
|
|
|
|
|
Total
|
1,000,000
|
Sch. I -
1
SCHEDULE II
|
Total Number
of
Option
Shares
|
|
|
Xxxxxxx
Xxxxxxx
|
150,000
|
|
|
|
|
|
|
Totals
|
150,000
|
Sch. II -
1
SCHEDULE III
Issuer
General Use Free Writing Prospectuses:
None
Permitted Free
Writing Prospectuses:
None
Other
Information Included in General Disclosure Package:
1.
The initial price
to the public of the shares, which is $15.00.
2.
The number of Firm
Shares, which is 1,000,000.
3.
The number of
Option Shares, which is 150,000.
Sch. III -
1
SCHEDULE IV
LIST OF ALL COMPANY SUBSIDIARIES
SharpSpring
Technologies, Inc., a Delaware corporation
SharpSpring
Reach, Inc., a Delaware corporation
InterInbox
SA, a Swiss corporation
ERNEPH
2012A (Pty) Ltd., a South African limited company
ERNEPH
2012B (Pty) Ltd., a South African limited company
SMTP
Holdings S.a.r.l., a Luxembourg S.a.r.l.
Sch. IV -
1
SCHEDULE V
FORM OF
LOCK-UP AGREEMENT
Sch. V -
1
FORM OF
LOCK-UP AGREEMENT
December
,
2020
Xxxxxxx & Company, LLC
Lake Street Capital Markets, LLC
As
Representatives of the several Underwriters
c/o
Needham & Company, LLC
000
Xxxx Xxxxxx, 00xx Xxxxx
Xxx
Xxxx, Xxx Xxxx 00000
x/x
Xxxx Xxxxxx Xxxxxxx Xxxxxxx, LLC
000
Xxxxxx Xxxxxx Xxxxx, Xxxxx 000
Xxxxxxxxxxx,
Xxxxxxxxx 00000
Ladies
and Gentlemen:
The
undersigned is a holder of securities of SharpSpring, Inc., a
Delaware corporation (the “Company”), and wishes to
facilitate the public offering of shares of the common stock, par
value $.001 per share (the “Common Stock”), of the
Company (the “Offering”). The
undersigned recognizes that such Offering will be of benefit to the
undersigned.
In consideration of the foregoing
and in order to induce you and the other underwriters for whom you
are acting as representatives to act as underwriters in connection
with the Offering, the undersigned hereby agrees that,
during the period commencing as of the date hereof and ending on
the date that is ninety (90) days after the date of the final
Prospectus Supplement relating to the Offering (the
“Lock-Up
Period”), the undersigned will not, without the prior
written approval of Xxxxxxx & Company, LLC, directly or
indirectly, (1) offer, pledge, sell, contract to sell, sell any
option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase, lend, or
otherwise transfer or dispose of any shares of Common Stock or any
securities convertible into or exercisable or exchangeable for
Common Stock (including Common Stock or such other securities that
may be deemed to be beneficially owned by the undersigned in
accordance with the rules and regulations of the Securities and
Exchange Commission and securities that may be issued upon exercise
of a stock option or warrant) (such shares of Common Stock and such
other securities collectively, the “Securities”), (2) enter
into any hedging, swap or other arrangement that transfers to
another, in whole or in part, any of the economic consequences of
ownership of the Securities, whether any such transaction described
in clause (1) or (2) above is to be settled by delivery of Common
Stock or such other securities, in cash or otherwise, (3) make any
demand for or exercise any right with respect to the registration
of any of the Securities, or (4) publicly disclose the intention to
do any of the foregoing. The undersigned acknowledges and agrees
that the foregoing precludes the undersigned from engaging in any
hedging or other transactions or arrangements (including, without
limitation, any short sale or the purchase or sale of, or entry
into, any put or call option, or combination thereof, forward, swap
or any other derivative transaction or instrument, however
described or defined) designed or intended, or which could
reasonably be expected to lead to or result in, a sale or
disposition or transfer (whether by the undersigned or any other
person) of any economic consequences of ownership, in whole or in
part, directly or indirectly, of any Securities, whether any such
transaction or arrangement (or instrument provided for thereunder)
would be settled by delivery of Securities, in cash or
otherwise;
Sch. V -
2
The
foregoing paragraph shall not apply to (a) the sale of Common Stock
in the Offering; (b) the transfer of shares of Common Stock or any
securities convertible into or exercisable or exchangeable for
Common Stock (A) to the spouse, domestic partner, parent, sibling,
child or grandchild of the undersigned or any other person with
whom the undersigned has a relationship by blood, marriage or
adoption not more remote than first cousin (each, an
“immediate family member”) or to a trust, or other
entity formed for estate planning purposes, formed for the direct
or indirect benefit of the undersigned or of an immediate family
member of the undersigned; (B) by bona fide gift, will or
intestacy; (C) if the undersigned is a corporation, partnership,
limited liability company or other business entity (1) to another
corporation, partnership, limited liability company or other
business entity that controls, is controlled by or is under common
control with the undersigned or (2) as part of a disposition,
transfer or distribution by the undersigned to its members, limited
partners or equity holders; or (D) if the undersigned is a trust,
to a trustor or beneficiary of the trust; provided that in the case
of any transfer or distribution pursuant to this clause (b), (x)
each transferee, trustee, donee or distributee shall sign and
deliver a lock-up agreement substantially in the form of this
agreement for the balance of the Lock-Up Period, and (y) no filing
under the Exchange Act shall be required or shall be voluntarily
made during the Lock-Up Period; (c) the receipt by the undersigned
from the Company of shares of Common Stock (the “Plan Shares”) upon the
vesting of restricted stock awards or exercise of options to
purchase the Company’s securities issued pursuant to the
Company’s equity incentive plans or the transfer of shares of
Common Stock or any securities convertible into Common Stock to the
Company upon a vesting event of the Company’s securities or
upon the exercise of options or warrants to purchase the
Company’s securities, in each case on a
“cashless” or “net exercise” basis or to
cover tax obligations of the undersigned in connection with such
vesting or exercise; provided that any filing under the
Securities Exchange Act of 1934, as amended (the
“Exchange
Act”) shall clearly indicate in the footnotes thereto
that the filing relates to such exercise, vesting, or sale or
transfer to cover tax withholding obligations and; provided further, that the Plan Shares
shall be subject to the terms of this Agreement; (d) the
establishment of a trading plan pursuant to Rule 10b5-1 under the
Exchange Act for the transfer of shares of Common Stock;
provided that (A) such plan
does not provide for the transfer of Common Stock during the
Lock-Up Period and (B) no public announcement or filing under the
Exchange Act is required of or voluntarily made by or on behalf of
the undersigned or the Company regarding the establishment of such
plan or (e) the transfer of shares of Common Stock or any security
convertible into or exercisable or exchangeable for Common Stock
that occurs by operation of law including pursuant to a qualified
domestic order or in connection with a divorce settlement;
provided that the
transferee signs and delivers a lock-up agreement substantially in
the form of this Agreement for the balance of the Lock-Up
Period.
In addition, the undersigned agrees
that, without the prior written consent of Xxxxxxx & Company,
LLC, the undersigned will not, during the Lock-Up Period, make any
demand for or exercise any right with respect to, the registration
of any shares of Common Stock or any security convertible into or
exercisable or exchangeable for Common Stock. The
undersigned confirms that he, she or it understands that the
underwriters and the Company will rely upon the representations set
forth in this Agreement in proceeding with the Offering. The
undersigned further confirms that the agreements of the undersigned
are irrevocable and shall be binding upon the undersigned’s
heirs, legal representatives, successors and assigns. The
undersigned agrees and consents to the entry of stop transfer
instructions with the Company’s transfer agent against the
transfer of securities held by the undersigned except in compliance
with this Agreement.
The
undersigned hereby consents to receipt of this Agreement in
electronic form and understands and agrees that this Agreement may
be signed electronically. In the event that any signature is
delivered by facsimile transmission, electronic mail, or otherwise
by electronic transmission evidencing an intent to sign this
Agreement, such facsimile transmission, electronic mail or other
electronic transmission shall create a valid and binding obligation
of the undersigned with the same force and effect as if such
signature were an original. Execution and delivery of this
Agreement by facsimile transmission, electronic mail or other
electronic transmission is legal, valid and binding for all
purposes.
Sch. V -
3
This
Agreement and any claim, controversy or dispute arising under or
related to this Agreement shall be governed by and construed in
accordance with the laws of the State of New York.
|
|
Very truly yours, |
|
|
|
|
|
|
|
/s/
|
|
|
(Signature)
|
|
|
|
|||
|
|
||
|
Sch. V -
4